Dermatologic Therapy最新文献

{"title":"Comprehensive Analysis of the Chemokine/Cytokine Profiles in Advanced Mycosis Fungoides and Atopic Dermatitis","authors":"Manami Takahashi-Watanabe,&nbsp;Taku Fujimura,&nbsp;Emi Yamazaki,&nbsp;Ryo Amagai,&nbsp;Kenta Oka,&nbsp;Yumi Kambayashi,&nbsp;Maki Ozawa,&nbsp;Tomoko Chiba,&nbsp;Mayuko Onodera-Amagai,&nbsp;Toshiya Takahashi,&nbsp;Yoshihide Asano","doi":"10.1155/dth/6603966","DOIUrl":"https://doi.org/10.1155/dth/6603966","url":null,"abstract":"<div>\u0000 <p>Mycosis fungoides (MF) is an indolent form of cutaneous T-cell lymphoma. Its early lesions are important to be distinguished from atopic dermatitis (AD) because of their similar immune microenvironment. We have previously demonstrated that several chemokines are involved in the pathogenesis of advanced MF. Therefore, we sought to comprehensively analyze the changes in the immune environment during the advanced phase of MF by focusing on serum cytokines and chemokines and to identify potential biomarkers for the early detection of the transition to the advanced phase of MF. Sera from 11 cases of advanced-stage MF, 16 cases of mild AD (median EASI score = 5.75), 16 cases of severe AD (median EASI score = 28.1), and 21 healthy volunteers were analyzed using the Bio-Plex 40 multiplex immunoassay system. The results revealed significant increases in immunosuppressive macrophage-related factors (IL-4, MIF, CCL3) in MF patients compared to those with AD and healthy controls. In contrast, IL-2, CCL1, CCL7, CCL21, CCL25, and CCL26 were significantly increased in severe AD patients compared to MF patients and healthy controls. Our findings suggest that several chemokines and cytokines contribute to an immunosuppressive environment favorable for tumor growth, distinguishing MF from AD. Moreover, T-cell proliferation and migration factors, which are mainly involved in maintaining inflammation, are elevated in severe AD compared to MF. In addition to elucidating the differences in the pathogenesis of these diseases, these factors may be important in the differential diagnosis of early MF and AD. Further studies are warranted to confirm these findings.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/6603966","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143900921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is Safety Profile of Apremilast in Elderly Patients Same With That in Young and Middle-Aged Patients? A Real-World Disproportionality Analysis of the FDA Adverse Event Reporting System","authors":"Chenyang Yu,&nbsp;Jinxin Qi,&nbsp;Wei Yan,&nbsp;Xian Jiang","doi":"10.1155/dth/8851158","DOIUrl":"https://doi.org/10.1155/dth/8851158","url":null,"abstract":"<div>\u0000 <p><b>Background and Objective:</b> Elderly individuals face heightened risks of infections, thrombosis, cardiovascular issues, and neoplasms, necessitating increased vigilance regarding adverse drug events (ADEs). The safety of apremilast in elderly patients has not been adequately explored in clinical trials. This study was to evaluate the safety profile of apremilast in young and middle-aged patients and elderly patients separately, through data mining of the US Food and Drug Administration Adverse Event Reporting System (FAERS).</p>\u0000 <p><b>Methods:</b> Reports in the FAERS from the third quarter of 2014 to the second quarter of 2023 were collected and analyzed. Disproportionality analyses (the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multi-item gamma Poisson shrinker (MGPS) algorithms) were employed to quantify the ADE signals of apremilast in the age groups of 18–65 years and over 65 years.</p>\u0000 <p><b>Results:</b> After data cleaning, a total of 54,926 and 14,156 ADE reports were retrieved, with 66 and 61 ADE signals identified in young and middle-aged patients and in elderly patients, respectively. Several unexpected ADE signals not listed in the drug labeling information were detected, including pericarditis, increased cholesterol levels, liver injury, postoperative thrombosis, serum calcium, and parathyroid abnormalities. Furthermore, weight loss, psychiatric abnormalities, and infections in particular sites (ear, bursa mucosa, and central nervous system) were more significant in elderly patients.</p>\u0000 <p><b>Conclusions:</b> The study indicated several unexpected ADEs through disproportionality analysis and highlighted unique safety features in the elderly group. These findings may assist clinicians in managing psoriasis with apremilast.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/8851158","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143875627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ixekizumab Restores Clinical Response in Patients With Hidradenitis Suppurativa After Secondary Loss of Effectiveness From Adalimumab: Results From a Retrospective Analysis of a Case Series","authors":"Caroline Hilbring,&nbsp;Matthias Augustin,&nbsp;Gefion Girbig,&nbsp;Armin Fatehi,&nbsp;Natalia Kirsten","doi":"10.1155/dth/5597039","DOIUrl":"https://doi.org/10.1155/dth/5597039","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> Hidradenitis suppurativa (HS) is a severe chronic inflammatory skin disease with a high burden of those affected. The tumor necrosis factor alpha (TNF-α)-inhibitor adalimumab was the first approved biologic in 2015, followed by secukinumab in 2023 and just recently, as of July 2024, the so far only selective dual IL-17A/F-inhibitor bimekizumab (Kimball et al. 2023). Analog to psoriasis treatment, there is still a strong need for further drug therapy options in case of primary nonresponse or secondary loss of effectiveness.</p>\u0000 <p><b>Objectives:</b> The study aim was to observe the effectiveness of ixekizumab in routine care for HS.</p>\u0000 <p><b>Methods:</b> We performed a retrospective analysis of structured data from ten patients with HS, treated with ixekizumab in 2019, after a secondary loss of effectiveness under adalimumab, at a time when adalimumab was still the only approved biologic for HS in Germany. Clinical response was measured using the International Hidradenitis Suppurativa Severity Score System (IHS4) and quality of life was assessed using the Dermatology Life Quality Index (DLQI) at baseline (week 0) and 16 weeks after the initiation of treatment.</p>\u0000 <p><b>Results:</b> Nine out of ten patients were female, mean age: 39.7 ± 11.0 years. The average IHS4 score decreased from 13.6 in week 0 to 9.6 in week 16. Three patients did not respond to treatment. DLQI resulted in an average decline of almost four points from 11.7 (week 0) to 7.8 (week 16).</p>\u0000 <p><b>Conclusions:</b> This case series indicates that a major proportion of patients with HS being treatment failures to adalimumab still respond to ixekizumab. Further studies with a larger study population are necessary to assess the long-term effectiveness and safety of ixekizumab in HS patients.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/5597039","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143865954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Diluted Calcium Hydroxyapatite Filler for Neck Rejuvenation: A Pilot Study on Single-Session, Short-Term Outcomes","authors":"Kui Young Park","doi":"10.1155/dth/1621113","DOIUrl":"https://doi.org/10.1155/dth/1621113","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> Calcium hydroxyapatite (CaHA) fillers are widely used in esthetic medicine for skin rejuvenation; however, their efficacy and safety for neck rejuvenation remain underexplored.</p>\u0000 <p><b>Objective:</b> To evaluate the clinical efficacy and safety of a diluted CaHA filler for improving skin barrier function, hydration, elasticity, and wrinkle severity in the neck.</p>\u0000 <p><b>Methods:</b> This 4-week prospective, single-center pilot study involved 10 volunteers aged 19–70 years with a horizontal neck wrinkle severity (HNWS) score of 2 or higher. A total of 4.8 mL of CaHA filler (VoLassom) mixed with normal saline (1:2 ratio) was injected into the subdermal layer of the neck using a 28-gauge needle across 24 points (three horizontal lines and eight points per line). Clinical outcomes, including transepidermal water loss (TEWL), skin hydration, elasticity, and HNWS, were assessed at baseline and at 2 and 4 weeks after treatment.</p>\u0000 <p><b>Results:</b> Nine participants completed the study. TEWL decreased significantly from 8.07 ± 1.53 g/m²/h at the baseline to 6.11 ± 2.17 g/m²/h at week four (<i>p</i> = 0.001), reflecting improved skin barrier function. Skin hydration increased from 57.72 ± 7.17 AU at the baseline to 64.78 ± 4.27 AU at week 4 (<i>p</i> = 0.01), and elasticity parameters (R2, R5, and R7) showed significant improvements (<i>p</i> &lt; 0.05). The HNWS score decreased from 2.44 ± 0.53 at the baseline to 1.00 ± 0.00 at week 4. No significant adverse events were observed.</p>\u0000 <p><b>Conclusion:</b> Diluted CaHA filler is a safe and effective option for neck rejuvenation, significantly improving skin barrier function, hydration, elasticity, and wrinkle severity within a short observational period.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/1621113","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143871462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Punch Excision Combined With Superficial X-Ray for the Treatment of Keloids: A Single-Center Retrospective Study","authors":"Junyou Zheng,&nbsp;Fang Fang,&nbsp;Wenbo Bu","doi":"10.1155/dth/4327219","DOIUrl":"https://doi.org/10.1155/dth/4327219","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> Keloid management remains a challenge for clinicians. Recently, punch excision and photoelectric technology have demonstrated promising clinical applications for managing keloids; however, few studies have examined the efficacy and safety of punch excision combined with superficial X-ray for treating keloids.</p>\u0000 <p><b>Objective:</b> To investigate the efficacy and safety of punch excision combined with superficial X-ray for treating keloid.</p>\u0000 <p><b>Methods:</b> In this retrospective study, we analyzed the clinical records of 60 patients with keloid scars who underwent punch excision combined with superficial X-ray at our hospital, from April 2020 to April 2023. The Vancouver Scar Scale (VSS) and Patient and Observer Scar Assessment Scale (POSAS) 2.0 Patient Scale serve as the primary assessment tools to evaluate all patients, both prior to the initial treatment and one year after the completion of therapy. SPSS software was used for statistical analysis to assess keloid improvement.</p>\u0000 <p><b>Results:</b> In the 60 patients with keloids, varying degrees of improvement were observed. The VSS and POSAS scores recorded 1 year after treatment were significantly lower than the pretreatment scores (<i>p</i> &lt; 0.001). No severe adverse reactions were observed during treatment.</p>\u0000 <p><b>Conclusion:</b> The combination of punch excision and superficial X-ray demonstrated a notable therapeutic effect on keloids without evident adverse reactions, offering a safe and effective option for patients with keloids.</p>\u0000 <p><b>Trial Registration:</b> Chinese Registry of Clinical Trials: ChiCTR2400094289</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/4327219","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143861644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Natural History and Prognostic Factors of Chronic Urticaria in Children Aged < 2 Years: A Single-Centered, Real-World, and Retrospective Study","authors":"Chun-Xiao Li,&nbsp;Hua-Guo Li,&nbsp;Bei-Bei Zhang,&nbsp;Yun Huang,&nbsp;Bei-Ming Wang,&nbsp;Yi-Hang Shen,&nbsp;Xiao-Xiao Wang,&nbsp;Wei-Qin Yang,&nbsp;Yan Gu,&nbsp;Yi-Feng Guo,&nbsp;Hui Zhang","doi":"10.1155/dth/1564070","DOIUrl":"https://doi.org/10.1155/dth/1564070","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> To date, a limited number of studies have reported on the natural course and prognostic factors of chronic urticaria (CU) among children aged &lt; 2 years.</p>\u0000 <p><b>Objective:</b> In this study, we delineated the characteristics and natural history of CU in children aged &lt; 2 years, with an additional aim of identifying prognostic factors closely associated with CU.</p>\u0000 <p><b>Methods:</b> This study included children aged &lt; 2 years who had CU between May 2019 and June 2023. The clinical data and laboratory results of these children were retrieved from their medical records or through telephone interviews.</p>\u0000 <p><b>Results:</b> The study population comprised 111 children with a median age of 16.30 (0.3–24) months at onset. Remission rates at 6, 12, and 36 months after the onset of CU were 36.08%, 51.55%, and 77.32%, respectively. After the sex and age at onset were adjusted, multivariate regression analysis revealed that allergic conjunctivitis was a risk factor for CU (OR_adjusted = 5.14 [95% CI, 1.03–28.52]).</p>\u0000 <p><b>Conclusion:</b> The course of CU in children aged &lt; 2 years is relatively short, with most children having a favorable outcome. Allergic conjunctivitis serves as a risk factor for CU in this age group.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/1564070","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143836126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pilot Study on the Efficacy of a Dual-Length Microneedle Radiofrequency Device With Microblade Design for Neck Rejuvenation","authors":"Ji Yeon Hong,&nbsp;Kui Young Park","doi":"10.1155/dth/8855222","DOIUrl":"https://doi.org/10.1155/dth/8855222","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> Neck aging presents challenges in achieving satisfactory cosmetic outcomes, particularly horizontal wrinkles. Minimally invasive technologies like microneedle radiofrequency (RF) devices offer promise for neck rejuvenation.</p>\u0000 <p><b>Aim:</b> This study evaluates the efficacy and safety of the novel microblade RF device for nonsurgical neck rejuvenation.</p>\u0000 <p><b>Methods:</b> Twelve healthy Korean volunteers received two microblade RF treatment sessions spaced 4 weeks apart. Skin biophysical properties were measured at baseline, Week 4, and Week 12. Assessments included Horizontal Neck Wrinkle Severity (HNWS) scores, Global Aesthetic Improvement Scale (GAIS) scores, and safety outcomes.</p>\u0000 <p><b>Results:</b> Significant reductions in HNWS scores were observed over time (<i>p</i> &lt; 0.001), alongside improved GAIS scores. Skin hydration increased, transepidermal water loss decreased, and skin elasticity improved at weeks 4 and 12. Treatment-related adverse effects were mild-to-moderate and transient, with no serious side effects reported.</p>\u0000 <p><b>Conclusion:</b> The microblade RF device demonstrates efficacy and safety for nonsurgical neck rejuvenation, with improvements in horizontal wrinkles and skin properties over time. These findings highlight its potential as a valuable tool in neck rejuvenation procedures.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/8855222","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143831402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allopurinol-Induced Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review of Case Reports and Case Series","authors":"Shirin Borjikhani,&nbsp;Sholeh Ebrahimpour,&nbsp;Mehdi Mohammadi","doi":"10.1155/dth/6527730","DOIUrl":"https://doi.org/10.1155/dth/6527730","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> Allopurinol is a known cause of mucocutaneous adverse drug reactions, including Stevens–Johnson syndrome and toxic epidermal necrolysis. The aim of this systematic review was to characterize the clinical presentation, identify risk factors, and evaluate the best treatment strategies for allopurinol-induced severe skin reactions.</p>\u0000 <p><b>Methods:</b> The PubMed, Embase, and Scopus databases were systematically searched to identify English case reports and case series of allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis. Animal studies, reviews, book chapters, randomized and nonrandomized human studies, observational studies, and conference abstracts were excluded. The Joanna Briggs Institute (JBI) critical appraisal checklists were used to assess the quality of the included studies.</p>\u0000 <p><b>Results:</b> Forty-seven case reports and 21 case series were included in the analysis, which reported 91 individual patient datasets. The reaction occurred after a median of 16 days (8.5 days in those with prior reactions to allopurinol). Rapid dose escalation was observed in half of the patients (21 of 43) for whom dose-increment schedules were reported. Mucosal involvement was observed in 72 (90.0%) patients. Corticosteroids, IVIG, cyclosporine, and plasma exchange were the most common treatment modalities. Twenty-one patients (23.6%) died, and 68 (76.4%) were discharged.</p>\u0000 <p><b>Conclusion:</b> Although gout is 2–3 times more common in men, the numbers of cases were similar in both sexes, likely due to higher reporting rates in women. Rapid dose escalation is a risk factor for the occurrence of severe skin reactions. Corticosteroids, IVIG, and plasma exchange appear to be reasonable treatment options.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/6527730","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143831405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Influence of Different Treatment Intervals on the Efficacy of Hemoporfin-Mediated Photodynamic Therapy in Pediatric Patients With Port-Wine Stain on the Periphery of the Face","authors":"Jun Zhou,&nbsp;Jingchen Liang,&nbsp;Lu Cui,&nbsp;Ying Chen,&nbsp;Hongshan Liu,&nbsp;Zhao Wang,&nbsp;Yawen Wang,&nbsp;Shengzhi Mu,&nbsp;Fan Yang,&nbsp;Jing Liu,&nbsp;Weihui Zeng","doi":"10.1155/dth/6223746","DOIUrl":"https://doi.org/10.1155/dth/6223746","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> Hemoporfin-mediated photodynamic therapy (Hemoporfin-PDT) is considered an effective treatment for Port-wine stain (PWS). However, no studies have explored the effects of different treatment intervals on the efficacy of Hemoporfin-PDT. This study aimed to analyze the impact of different treatment intervals on the efficacy of Hemoporfin-PDT in pediatric facial PWS patients.</p>\u0000 <p><b>Methods:</b> A retrospective analysis was conducted based on the clinical data of 95 pediatric facial PWS patients who received Hemoporfin-PDT treatment from March 2018 to October 2023 in our center. The association between efficacy and sex, age, and treatment interval was analyzed.</p>\u0000 <p><b>Results:</b> After three sessions of Hemoporfin-PDT, 87.37% of patients achieved excellent or good efficacy, 11.58% had fair efficacy, and 1.05% had poor efficacy. The efficacy of patients with a 9-month treatment interval was significantly inferior to those with 3-month and 6-month intervals (OR: 6.99, 95% CI: 1.63–30.02, <i>p</i> = 0.009; OR: 10.92, 95% CI: 2.18–54.76, <i>p</i> = 0.004). However, there was no significant difference between patients with 3-month and 6-month intervals (<i>p</i> = 0.45). Sex and age were not found to be associated with the efficacy of Hemoporfin-PDT.</p>\u0000 <p><b>Conclusion:</b> In pediatric PWS patients with pink-type lesions located on the peripheral face, clinical efficacy is associated with the treatment interval. The efficacy of patients with a 9-month treatment interval is significantly inferior to those with 3-month and 6-month intervals. While the influence of age on the efficacy of Hemoporfin-PDT remains inconclusive, we still believe that early initiation of treatment is beneficial and necessary.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/6223746","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143831406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Water Bathing on Atopic Dermatitis Are Determined by the Constituents in the Water","authors":"Dongyun Lei,&nbsp;Jiechen Zhang,&nbsp;Bijun Xia,&nbsp;Tingting Zhu,&nbsp;Lin Li,&nbsp;Canyi Gong,&nbsp;Litao Zhang,&nbsp;Mao-Qiang Man","doi":"10.1155/dth/3695790","DOIUrl":"https://doi.org/10.1155/dth/3695790","url":null,"abstract":"<div>\u0000 <p>Atopic dermatitis (AD) is a common skin disorder. Although a wide range of therapeutic regimens are available, they have some limitations, including high medical costs. However, evidence suggests that adjuvant regimens such as water bathing are inexpensive and effective approaches for the management of AD. Bathing with either tap water or seawater alone can improve AD symptoms and signs. Combination of water bathing with topic emollient or corticosteroids can synergically alleviate AD. The underlying mechanisms by which water bathing benefits AD include improvements in epidermal function, inhibition of mast cell and Langerhans cell function, reductions in serine protease expression and activity, inhibition of cytokine expression, and upregulation of expression levels of antioxidant enzymes, as well as antimicrobial peptides. In this review, we summarize the effects of water bathing on AD in both humans and murine models as well as the underlying mechanisms.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/3695790","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143818507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}